The results of the trial suggested that Adva-27 is 16-times more effective at killing Multidrug Resistant Breast Cancer cells in comparison to Etoposide.
Additionally, the data from the trial proved that Adva-27a is unaffected by the molecular machinery which are responsible for making cancer cells resistant to drugs.
Sunshine president and CEO Steve Slilaty said Adva-27a now offers a chemical structure which can be used as a basis for studying the mechanism of action of P-Glycoprotein as well as for the development of new drugs which can overcome the resistance caused by P-Glycoprotein and similar enzymes.